An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Stage Parkinson's Disease

Interventions

DRUG: Pardoprunox

Sponsor

Solvay Pharmaceuticals